3845 |
KRAS PROTO-ONCOGENE, GTPASE |
KRAS |
C-K-RAS |
CFC2 |
K-RAS2A |
K-RAS2B |
K-RAS4A |
K-RAS4B |
K-Ras |
KI-RAS |
KRAS1 |
KRAS2 |
NS |
NS3 |
RALD |
RASK2 |
c-Ki-ras2 |
190070 |
6407 |
ENSG00000133703 |
OTTHUMG00000171193 |
PA30196 |
3485 |
P01116 |
30 |
GTPase KRas |
T48598 |
'C-K-RAS |
K-Ras 2 |
OES |
c-Ki-ras |
CancerCommons Reported Gene Name | KRAS-RAS |
Target Class | Miscellaneous |
Target Subclass | Miscellaneous |
Target Subclass | Hras |
Gene Biotype | PROTEIN_CODING |
DRUG RESISTANCE |
CLINICALLY ACTIONABLE |
n/a |
Variant Effect | gain-of-function |
Pathway | activation |
Clinical Status | FDA-rejected |
n/a |
Clinical Status | late trials |
Pathway | activation |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
combination therapy | Reolysin + Gemcitabine |
Indication/Tumor Type | pancreatic cancer |
Response Type | sensitive |
n/a |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | predicted – sensitive |
Approval Status | Preclinical - Pdx |
inhibitor (inhibitory) |
combination therapy | Osimertinib + Selumetinib |
Indication/Tumor Type | thyroid cancer |
combination therapy | Dasatinib + Selumetinib |
n/a |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | decreased response |
Approval Status | Preclinical - Cell culture |
n/a |
combination therapy | Pazopanib + Trametinib |
Indication/Tumor Type | thyroid cancer |
combination therapy | Dasatinib + Trametinib |
n/a |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | no benefit |
Approval Status | Preclinical |
n/a |
combination therapy | Pimasertib + Gemcitabine |
Indication/Tumor Type | pancreatic cancer |
Response Type | sensitive |
n/a |
combination therapy | Atezolizumab + Cobimetinib |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted – sensitive |
n/a |
combination therapy | SCH772984 + Temsirolimus |
Indication/Tumor Type | pancreatic ductal adenocarcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Indication/Tumor Type | breast cancer |
Approval Status | Preclinical - Cell line xenograft |
Approval Status | Preclinical - Cell culture |
n/a |
combination therapy | ABT-263 + Alpelisib + Erlotinib + Trametinib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
combination therapy | Irinotecan + Selumetinib |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted – sensitive |
n/a |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | predicted – sensitive |
Approval Status | Phase I |
n/a |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
n/a |
Evidence Type | Actionable |
Approval Status | Preclinical |
Response Type | sensitive |
n/a |
combination therapy | Bevacizumab + Capecitabine |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted – sensitive |
n/a |
KRAS | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
3485 | Entrez Gene ID |
CancerCommons Reported Gene Name | KRAS-RAS |
KRAS | Gene Symbol |
Target Class | Miscellaneous |
Target Subclass | Miscellaneous |
Target Subclass | Hras |
3845 | CKB Entrez Id |
KRAS | CKB Gene Synonym |
C-K-RAS | CKB Gene Synonym |
PA30196 | PharmGKB ID |
3845 | Entrez Gene ID |
30 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
K-RAS | Gene Symbol |
RASK2 | OncoKB Gene Synonym |
3845 | OncoKB Entrez Id |
KI-RAS | OncoKB Gene Synonym |
KRAS | Gene Symbol |
CLINICALLY ACTIONABLE |
KRAS | TTD Gene Abbreviation |
T48598 | TTD Target ID |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |